The lawsuit, filed by a group of buyers in 2006, alleges Mylan delayed putting its generic version of Cephalon’s sleeping pill Provigil on the market in exchange for payment from Cephalon, according to the report.
Through the settlement, Mylan will offer buyers — defined as all persons or entities in the U.S. who bought Provigil directly from Cephalon between June 24, 2006, and Aug. 31, 2012 —their allocated share of the settlement fund, excluding legal fees, reports Bloomberg.
The agreement is still pending approval by U.S. District Judge Mitchell Goldberg.
More articles on supply chain:
Express Scripts: Drug spending slowed in 2016
Study: Amgen’s Repatha lowers risk of heart problems
Government subpoenas Biogen over MS drug prices
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
